Gsa Capital Partners LLP Clovis Oncology, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $418,990 - $1.14 Million	399,039 New	399,039 $475,000
Q1 2021 May 10, 2021	SELL	$4.81 - $10.34 $99,595 - $214,100	-20,706 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$4.13 - $6.41 $85,515 - $132,725	20,706 New	20,706 $99,000
Q2 2020 Aug 11, 2020	SELL	$5.69 - $9.69 $88,627 - $150,931	-15,576 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$3.77 - $11.0 $14,725 - $42,966	-3,906 Reduced 20.05%	15,576 $99,000
Q4 2019 Feb 12, 2020	SELL	$3.0 - $16.43 $23,088 - $126,445	-7,696 Reduced 28.32%	19,482 $203,000
Q3 2019 Nov 12, 2019	BUY	$3.93 - $15.35 $106,809 - $417,182	27,178 New	27,178 $107,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.